Business Wire

DermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting

- Phase 2 proof of concept trial met primary endpoint of a one-point improvement in PLA score at last visit and safety via local tolerability in 35 patients with seborrheic keratoses (SKs) target ...
Business Wire

DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for these Common Benign Tumors

52% of SKs lesions treated for 28 days cleared completely, reaching a PLA score of 0. 100% of SKs lesions treated for 28 days demonstrated at least a one-point drop in their PLA score and patients ...